Protains CTO Yash Sharma Announces Partnership with NVIDIA to Leverage H100 Clusters for Drug Discovery

Protains is excited to announce a new partnership with NVIDIA to utilize their cutting-edge H100 GPU clusters specifically for AI-driven drug discovery. Yash Sharma, CTO of Protains, shared the news, emphasizing how this collaboration will enhance Protains' computational power and accelerate breakthroughs in pharmaceutical research.

Yash Sharma's Statement on the NVIDIA Partnership

We are thrilled to announce our partnership with NVIDIA to harness the immense computational power of H100 clusters. This collaboration will allow us to process complex biological data at an unprecedented scale and speed, drastically improving our ability to discover and develop new drug candidates. NVIDIA’s H100 GPUs are the gold standard for AI workloads, and this will give us the computational resources necessary to continue pushing the limits of what AI can achieve in drug discovery.

Powering the Future of Drug Discovery with NVIDIA H100

NVIDIA’s H100 GPUs are designed to handle the most demanding AI workloads, offering unparalleled performance for large-scale models like those used at Protains. By managing these clusters, Protains will be able to run more sophisticated simulations, analyze massive datasets, and generate more accurate predictions for drug candidate efficacy.

This partnership represents a significant leap forward in Protains’ mission to transform the pharmaceutical industry, giving its AI platform the computational horsepower to drive faster, more cost-effective drug discovery.